Phaseline

Targets › THRA

THRA (Thyroid hormone receptor alpha): drug programs, companies and trials

12 programs from 12 companies in 15 trials: 6 Phase 2, 4 Phase 4, 3 Phase 3, 2 Phase 1; Metabolic and endocrine, Other, Genitourinary; next expected readout Nov 2026.

[Isoform Alpha-1]: Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine..; FUNCTION: [Isoform Alpha-2]: Does not bind thyroid hormone and functions as a weak dominant negative inhibitor of thyroid hormone action. (UniProt, P10827)

Open in Phaseline: the race on THRA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Elyes KamounLevothyroxine
Thyroid hormone receptor agonist
THRA, THRBPhase 4Hypothyroidism PrimaryDec 2026
University of PennsylvaniaLevothyroxine Sodium
Thyroid hormone receptor agonist
THRA, THRBPhase 4HypothyroidismApr 2028
Daihong LiuAnti-Thymocyte Globulin (ATG) (Thymoglobulin)
Anti-thymocyte immunoglobulin; depletes T cells through immune recognition
THRA, THRBPhase 4Hematopoietic Stem Cell TransplantationAug 2028
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludLevothyroxine
Thyroid hormone receptor agonist
THRA, THRBPhase 3ObesityNov 2026
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoLevothyroxine
Thyroid hormone receptor agonist
THRA, THRBPhase 3Hypothyroidism; IrradiationSep 2029
Rare Thyroid Therapeutics InternationalTiratricol
Thyroid hormone receptor agonist
THRA, THRBPhase 2Allan-Herndon-Dudley SyndromeJul 2027
AbbVieArmour Thyroid
Thyroid hormone replacement containing levothyroxine (T4) and liothyronine (T3)
THRA, THRBPhase 2HypothyroidismSep 2027
SAb BiotherapeuticsSAB-142
Human anti-thymocyte immunoglobulin
THRAPhase 2Type 1 DiabetesNov 2027
UConn HealthLevothyroxine
Thyroid hormone receptor agonist
THRA, THRBPhase 2HypothyroidismDec 2027
VA Office of Research and DevelopmentLevothyroxine Sodium
Thyroid hormone receptor agonist
THRA, THRBPhase 2Nonalcoholic SteatohepatitisDec 2029
Jeffrey Veale, MDrabbit anti-thymocyte globulin (rATG)
Polyclonal immunoglobulin that depletes T cells by binding to thymocyte antigens
THRAPhase 1Renal Transplant RejectionMay 2027
Stephan Busquerabbit Anti-Thymocyte Globulin (rATG)
Polyclonal antibody targeting T cells to deplete recipient lymphocytes
THRAPhase 1Immune ToleranceOct 2028

Conditions

Hypothyroidism (4) Hematopoietic Stem Cell Transplantation (3) Renal Transplant Rejection (1) Hypothyroidism; Irradiation (1) Hypothyroidism Primary (1) Obesity (1) Allan-Herndon-Dudley Syndrome (1) Immune Tolerance (1) Type 1 Diabetes (1) Nonalcoholic Steatohepatitis (1)

Modalities

small molecule (9), other (2), protein or peptide (1)

Companies

Daihong Liu (1) Jeffrey Veale, MD (1) Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) Elyes Kamoun (1) Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (1) Rare Thyroid Therapeutics International (1) Stephan Busque (1) AbbVie (1) SAb Biotherapeutics (1) University of Pennsylvania (1) UConn Health (1) VA Office of Research and Development (1)

Related targets

THRB (9)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.